GlassScriptPhysician profile
Brooke E Rhodes
NPI 1346686938
$2,971.55
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $423 · 2022: $566 · 2023: $984 · 2024: $998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,789 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,788.58 |
| Education | $193.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $422.11 | 2022-2024 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $421.43 | 2021-2024 | |
| Exeltis, USA INC. | $293.54 | 2021-2024 | Slynd, Solosec, Tyblume |
| Shield Therapeutics INC | $253.27 | 2024 | |
| Exact Sciences Corporation | $185.39 | 2023-2024 | Cologuard Collection Kit |
| Organon LLC | $174.27 | 2021-2024 | Nexplanon |
| Novo Nordisk INC | $161.17 | 2022-2024 | Wegovy, Saxenda |
| Therapeuticsmd, INC. | $146.26 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $133.21 | 2021-2024 | |
| Abbvie INC. | $101.12 | 2021-2024 | |
| Currax Pharmaceuticals LLC | $86.95 | 2021-2023 | Onzetra Xsail, Nexletol, Contrave |
| Pfizer INC. | $76.27 | 2023-2024 | |
| Mylan Pharmaceuticals INC. | $61.10 | 2021-2022 | |
| Myovant Sciences INC. | $51.20 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $48.75 | 2023 | Myfembree |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $47.58 | 2021-2023 | Phexxi |
| Myriad Women'S Health, INC. | $45.61 | 2023 | Myrisk |
| Amgen INC. | $45.59 | 2023-2024 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $41.60 | 2021-2022 | |
| Hologic Sales and Service, LLC | $38.64 | 2022-2023 | Aptima, Thinprep 2000 Processor |
| Lilly USA, LLC | $30.26 | 2024 | Zepbound |
| Ascend Therapeutics US, LLC | $23.90 | 2022 | |
| Roche Diagnostics Corporation | $20.11 | 2021 | |
| Lupin INC. | $19.68 | 2021 | |
| Sage Therapeutics, LLC | $15.23 | 2024 | |
| Virtus Pharmaceuticals LLC | $14.20 | 2021 | |
| Xeris Pharmaceuticals, INC. | $13.11 | 2024 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Rhodes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.